Assenagon Asset Management S.A. Trims Holdings in Hologic, Inc. $HOLX

Key Points

• Assenagon Asset Management S.A. has reduced its stake in Hologic, Inc. by 59.2%, leaving it with 186,652 shares valued at approximately $12.16 million.
• Hologic recently reported quarterly earnings of $1.08 EPS, exceeding analyst expectations, and its revenue increased by 1.2% year-over-year to $1.02 billion.
• Several institutional investors, including Victory Capital Management Inc., have been increasing their holdings in Hologic, contributing to institutional ownership now at 94.73% of the company's stock.

Assenagon Asset Management S.A. decreased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 59.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 186,652 shares of the medical equipment provider's stock after selling 270,888 shares during the period. Assenagon Asset Management S.A. owned about 0.08% of Hologic worth $12,162,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Victory Capital Management Inc. increased its stake in Hologic by 34.4% in the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after purchasing an additional 1,692,177 shares during the period. Invesco Ltd. grew its position in shares of Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after buying an additional 764,573 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Hologic by 1.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider's stock worth $276,303,000 after buying an additional 69,878 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Hologic by 0.8% during the 1st quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider's stock worth $216,973,000 after buying an additional 29,133 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Hologic by 8.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider's stock worth $175,331,000 after buying an additional 213,366 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Trading Up 1.4%

Shares of NASDAQ:HOLX opened at $67.29 on Tuesday. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The stock has a market cap of $14.97 billion, a price-to-earnings ratio of 27.92, a PEG ratio of 2.40 and a beta of 0.57. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The business has a 50-day moving average price of $66.53 and a 200-day moving average price of $62.77.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same period last year, the business posted $1.06 earnings per share. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on HOLX. Evercore ISI increased their price target on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and increased their price target for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Argus increased their price target on Hologic from $80.00 to $90.00 and gave the stock a "buy" rating in a research report on Friday. UBS Group raised their price objective on Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research report on Thursday, July 31st. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, Hologic presently has a consensus rating of "Moderate Buy" and a consensus price target of $79.38.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.